title: Positron emission tomography and colorectal cancer.
abstract: Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality. Molecular imaging using positron emission tomography (PET) is now an integral part of multidisciplinary cancer care. In this review, we discuss the role of PET in CRC including well established indications in the assessment of recurrent disease and emerging applications such as initial staging, monitoring therapy efficacy and using PET for radiotherapy planning. With rapid advancement in imaging technology, we also discuss the future potential of combining PET and magnetic resonance imaging and the use of novel radiotracers.
authors.affiliation: Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, Australia; University of New South Wales, Sydney, Australia. michael.lin@swsahs.nsw.gov.au
authors.forename: Michael
authors.initials: M
authors.lastname: Lin
authors.forename: Karen
authors.initials: K
authors.lastname: Wong
authors.forename: Weng Leong
authors.initials: WL
authors.lastname: Ng
authors.forename: Ivan Ho
authors.initials: IH
authors.lastname: Shon
authors.forename: Matthew
authors.initials: M
authors.lastname: Morgan
mesh_terms: D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000628:therapy; D055088:Early Detection of Cancer / Q000379:methods*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000592:standards* / Q000639:trends; D011379:Prognosis
chemical_list: D019788:Fluorodeoxyglucose F18